Top Tweets for #TAS102

Oncology Brothers

over 2 years ago

Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023: - #Tucatinib - Mountaineer - #TAS102 + #Bevacizumab - Sunlight - #Pembro + Cis/Gem - KN966 - #Fruquintinib - FRESCO2 - #Pembro + Chemo - KN859 #OncTwitter #gism #crcsm

OncBrothers's tweet photo. Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023:

- #Tucatinib - Mountaineer
- #TAS102 + #Bevacizumab - Sunlight
- #Pembro + Cis/Gem - KN966
- #Fruquintinib - FRESCO2
- #Pembro + Chemo - KN859

#OncTwitter #gism #crcsm https://t.co/RduaJ9F3LD

Oncology Brothers

over 3 years ago

Summary of the 4 new drugs/indications that were approved for GI malignancies by @FDAOncology in 2022: - Nivo & Ipi/Nivo - Durvalumab - Futibatinib - Treme + Durva #GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology #gism

OncBrothers's tweet photo. Summary of the 4 new drugs/indications that were approved for GI malignancies by @FDAOncology in 2022:

- Nivo & Ipi/Nivo
- Durvalumab
- Futibatinib
- Treme + Durva

#GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology #gism https://t.co/aGO5p4CJFf

0

113

43

20

51K

2

128

55

25

57K

Tribunek_Onco @TribuneKa

over 3 years ago

Retrouvez dans notre rubrique Tumeurs Gastro-intestinales, l’analyse commentée rédigée par David TOUGERON sur l’article de André T, et al. Lancet Gastroenterol Hepatol 2023 ➡️ https://t.co/ArJnFjOb49 #cancers #colorectaux #TAS102 #SOLSTICE

TribuneKa's tweet photo. Retrouvez dans notre rubrique Tumeurs Gastro-intestinales, l’analyse commentée rédigée par David TOUGERON sur l’article de André T, et al. Lancet Gastroenterol Hepatol 2023 ➡️ https://t.co/ArJnFjOb49
#cancers #colorectaux #TAS102 #SOLSTICE https://t.co/YyG3nKyMuV

0

2

0

0

144

Jun Gong, MD @jgong15

over 3 years ago · San Francisco

Dr. Deming discussant on Ph III SUNLIGHT #TAS102 + bev superior to active control TAS102 (median OS 10.8 vs 7.5 mos) in unselected #3L+ met #crcsm new reference standard in refractory #mCRC @OncoAlert @ASCO #GI23

$jgong15's tweet photo. Dr. Deming discussant on Ph III SUNLIGHT #TAS102 + bev superior to active control TAS102 (median OS 10.8 vs 7.5 mos) in unselected #3L+ met #crcsm new reference standard in refractory #mCRC @OncoAlert @ASCO #GI23 https://t.co/vUb754YKHF$

$jgong15's tweet photo. Dr. Deming discussant on Ph III SUNLIGHT #TAS102 + bev superior to active control TAS102 (median OS 10.8 vs 7.5 mos) in unselected #3L+ met #crcsm new reference standard in refractory #mCRC @OncoAlert @ASCO #GI23 https://t.co/vUb754YKHF$

$jgong15's tweet photo. Dr. Deming discussant on Ph III SUNLIGHT #TAS102 + bev superior to active control TAS102 (median OS 10.8 vs 7.5 mos) in unselected #3L+ met #crcsm new reference standard in refractory #mCRC @OncoAlert @ASCO #GI23 https://t.co/vUb754YKHF$

$jgong15's tweet photo. Dr. Deming discussant on Ph III SUNLIGHT #TAS102 + bev superior to active control TAS102 (median OS 10.8 vs 7.5 mos) in unselected #3L+ met #crcsm new reference standard in refractory #mCRC @OncoAlert @ASCO #GI23 https://t.co/vUb754YKHF$

3

35

9

6

7K

Sumanta K. Pal, MD, FASCO

about 4 years ago

Proud of @cityofhope fellow #DrJeremyChuang (is he on @Twitter, @arafflemd?) who authored this paper w @jgong15 @CedarsSinaiMed & GI program lead @mgfakih evaluting #trametinib w #TAS102 in chemoR RASm mCRC. @stacywgray @DrRaviSalgia @cityofhopeoc @COHMedOnc

montypal's tweet photo. Proud of @cityofhope fellow #DrJeremyChuang (is he on @Twitter, @arafflemd?) who authored this paper w @jgong15 @CedarsSinaiMed & GI program lead @mgfakih evaluting #trametinib w #TAS102 in chemoR RASm mCRC. @stacywgray @DrRaviSalgia @cityofhopeoc @COHMedOnc https://t.co/GnM0KV0NGa

0

22

8

0

0

がんナビ通信 @cancer_navi

almost 7 years ago

FTD/TPIが癌化学療法後に増悪した進行・再発胃癌へ適応拡大：がんナビ進行胃がんに新たな治療薬が登場しました。 #がんナビ #胃がん #FTDTPI #TAS102 https://t.co/ulmzcPQqxv

0

2

2

0

0

Arturo LoAIza-Bonilla, MD MSEd

over 7 years ago · San Francisco

Analysis Sustains TAS-102 Survival Benefit in Gastric Cancer https://t.co/6qRT8NXESo? via @onclive #GI19 #gastriccancer @StomachCancer_ @CancerCenter @TaihoOncology #tas102 #cancerresearch #clinicaltrials

0

2

0

0

0

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users